The role of polymorphism of the epidermal growth factor gene in the formation of severe manifestations of skin toxicity caused by the use of EGFR inhibitors
- Authors: Orlova E.V.1, Olisova O.Y.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
- Issue: Vol 26, No 5 (2023)
- Pages: 431-439
- Section: DERMATO-ONCOLOGY
- URL: https://journals.rcsi.science/1560-9588/article/view/232061
- DOI: https://doi.org/10.17816/dv108023
- ID: 232061
Cite item
Abstract
Epidermal growth factor receptor (EGFR) inhibitors are widely used to treat various types of cancer, such as non-small cell lung cancer, head and neck cancer, breast cancer, pancreatic cancer, colorectal cancer. During treatment, class-mediated effects such as skin toxicity, interstitial lung disease, hepatotoxicity, ocular toxicity, hypomagnesemia, stomatitis, and diarrhea may occur. The role of epidermal growth factor and its receptors in the vital activity of keratinocytes is key. Dermatological undesirable effects occur in 60–90% of patients, and often persist throughout the entire period of EGFR inhibitor therapy.
Currently, studies of biomarkers predicting the severity of skin complications of EGFR inhibitor therapy are extremely limited. Thus, it is relevant to study genetic markers reliably associated with the development of severe skin toxicity against the background of EGFR inhibitor therapy, because the EGFR signaling pathway is important for maintaining normal physiological function of the skin. The development of severe skin reactions leads to a reduction in the dose or discontinuation of EGFR inhibitors in the treatment of cancer. Recently, progress has been made in studies of the cutaneous toxicity of EGFR inhibitors.
Here we briefly describe the mechanism of skin toxicity caused by EGFR inhibitors, current data on the relationship of gene polymorphism and severity of manifestations of undesirable dermatological phenomena.
Full Text
##article.viewOnOriginalSite##About the authors
Ekaterina V. Orlova
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Author for correspondence.
Email: orlovaderm@yandex.ru
ORCID iD: 0000-0002-1684-8781
MD, Cand. Sci. (Med.)
Russian Federation, 4/1 Bolshaia Pirogovskaia street, 119435 MoscowOlga Yu. Olisova
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Email: olisovaolga@mail.ru
ORCID iD: 0000-0003-2482-1754
SPIN-code: 2500-7989
MD, Dr. Sci. (Med.), Professor, Corresponding member of the Russian Academy of Sciences
Russian Federation, MoscowReferences
- Uribe ML, Marrocco I, Yarden Y. EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance. Cancers. 2021;13(11):2748. doi: 10.3390/cancers13112748
- Reiter JL, Threadgill DW, Eley GD, et al. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics. 2001;71(1):1–20. doi: 10.1006/geno.2000.6341
- Kubo A, Hashimoto H, Takahashi N, Yamada Y. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer. World J Gastroenterol. 2016;22(2):887–894. doi: 10.3748/wjg.v22.i2.887
- Lacouture ME, Rodeck U. Skinflammation and drug toxicity: A delicate balance. Sci Transl Med. 2013;5(199):199fs33. doi: 10.1126/scitranslmed.3006993
- Popa C, Lungulescu C, Ianoși SL, et al. Molecular profiling of EGFR status to identify skin toxicity in colorectal cancer: A clinicopathological review. Curr Health Sci J. 2019;45(2):127–133. doi: 10.12865/CHSJ.45.02.01
- Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(Suppl 1):31–39. doi: 10.1007/s40257-018-0384-3
- Skin side effects of molecular targeted therapy and other biological agents used to treat cancer. Available from: https://www.uptodate.com/contents/cutaneous-adverse-events-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy. Accessed: 05.05.2023.
- Lorch JH, Klessner J, Park JK, et al. Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J Biol Chem. 2004;279(35):37191–37200. doi: 10.1074/jbc.M405123200
- Woodworth CD, Michael E, Marker D, et al. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther. 2005;4(4):650–658. doi: 10.1158/1535-7163.MCT-04-0238
- Gerber PA, Buhren BA, Schrumpf H, et al. Mechanisms of skin aging induced by EGFR inhibitors. Support Care Cancer. 2016;24(10):4241–4248. doi: 10.1007/s00520-016-3254-7
- Nanney LB, Stoscheck CM, King L, et al. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol. 1990;94(6):742–748. doi: 10.1111/1523-1747.ep12874601
- Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56(2):317–326. doi: 10.1016/j.jaad.2006.09.005
- Holcmann M, Sibilia M. Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol. 2015;2(4):e1004969. doi: 10.1080/23723556.2015.1004969
- Orlova EV. Physiological functions of keratinocyte epidermal growth factor receptors and their role in the development of skin toxicity during targeted cancer therapy. Russ J Skin Venereal Dis. 2021;24(2):111–118. (In Russ). doi: 10.17816/dv63506
- Han SS, Lee M, Park GH, et al. Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines. Br J Dermatol. 2010;162(2):371–379. doi: 10.1111/j.1365-2133.2009.09536.x
- Matsumura S, Terao M, Itami S, Katayama I. Local cortisol activation is involved in EGF-induced immunosuppression. Dermatoendocrinol. 2017;9(1):e1412018. doi: 10.1080/19381980.2017.1412018
- Lichtenberger BM, Gerber PA, Holcmann M, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med. 2013;5(199):199ra111. doi: 10.1126/scitranslmed.3005886
- Firat YH, Simanski M, Rademache F, et al. Infection of keratinocytes with trichophytum rubrum induces epidermal growth factor-dependent rnase 7 and human beta-defensin-3 expression. PLoS One. 2014;9(4):e93941. doi: 10.1371/journal.pone.0093941
- Lulli D, Carbone ML, Pastore S. Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin. Oncotarget. 2016;7(30):47777–47793. doi: 10.18632/oncotarget.10013
- Satoh TK, Mellett M, Meier-Schiesser B, et al. IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. J Clin Invest. 2020;130(3):1417–1430. doi: 10.1172/JCI128678
- Urban C, Anadkat MJ. A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers. J Gastrointest Oncol. 2013;4(3):319–327. doi: 10.3978/j.issn.2078-6891.2013.033
- Fang H, Wang Y, Xu L, et al. EGFR inhibitor gefitinib regulates barrier function in human epidermal keratinocytes via the modulation of the expression of claudins. Int J Mol Med. 2019;43(3):1522–1530. doi: 10.3892/ijmm.2018.4046
- Baas J, Krens L, Bohringer S, et al. Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. PLoS One. 2018;13(12):e0208080. doi: 10.1371/journal.pone.0208080
- Froelich MF, Stintzing S, Kumbrink J, et al. The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximab. Oncotarget. 2018;9(54):30279–30288. doi: 10.18632/oncotarget.25689
- Jaka A, Gutiérrez-Rivera A, Ormaechea N, et al. Association between EGFR gene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients. Exp Dermatol. 2014;23(10):751–753. doi: 10.1111/exd.12510
- Fernández-Mateos J, Seijas-Tamayo R, Mesía R, et al. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population. Oral Oncology. 2016;(63):38–43. doi: 10.1016/j.oraloncology.2016.10.006
- Obradovic J, Todosijevic J, Jurisic V. Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: A systematic review and meta-analysis. Oncol Lett. 2023;25(2):62. doi: 10.3892/ol.2022.13649
- Saito R, Suzuki H, Yamada T, et al. Predicting skin toxicity according to EGFR polymorphisms in patients with colorectal cancer receiving antibody against EGFR. Anticancer Res. 2013;33(11):4995–4998.
- Huang CL, Yang CH, Yeh KH, et al. EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer. 2009;64(3):346–351. doi: 10.1016/j.lungcan.2008.09.009
- Hasheminasab SM, Tzvetkov MV, Schumann C, et al. High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors. Pharmacogenomics. 2015;16(14):1605–1619. doi: 10.2217/pgs.15.97
- Klinghammer K, Knödler M, Schmittel A, et al. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res. 2010;16(1):304–310. doi: 10.1158/1078-0432.CCR-09-1928
- Parmar S, Schumann C, Rüdiger S, et al. Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. Pharmacogenomics J. 2013;13(2):181–188. doi: 10.1038/tpj.2011.51
![](/img/style/loading.gif)